The FDA said in a statement that it had determined that one of the two approved vaccines, Ixchiq (Valneva SE), which contains ...

According to the vaccine's maker, Valneva, the FDA based its decision to suspend the shot on four new serious adverse events ...

FDA suspends Ixchiq license, raising regulatory risks for Valneva. Key vaccines anchor revenue, but valuation concerns emerge ...

In a U-turn from a decision two weeks ago, the FDA – citing new safety events – said the vaccine is a ‘danger to health’.

Valneva shares fall after FDA suspends Ixchiq vaccine license citing new safety reports, raising questions over future U.S.

The FDA suspends Ixchiq, the only approved chikungunya vaccine, over safety concerns, impacting its availability in the U.S.

US health authorities have suspended the license for the Ixchiq vaccine against the chikungunya virus following reports of ...

Earlier this month, the FDA backed off on a pause in shipments of the chikungunya vaccine Ixchiq to older adults. Now, the ...

Shares of French drugmaker Valneva slumped more than 20% on Monday after the U.S. Food and Drug Administration suspended the ...

Reports of side effects have prompted reviews in particular over its use in older patients. Read more at straitstimes.com.

Less than three weeks after lifting a pause on the use of Valneva’s chikungunya vaccine Ixchiq, the FDA has done an ...